Dynamics of Prolyl hydroxylases levels during disease progression in experimental colitis

Hamid A. Bakshi, Vijay Mishra, Saurabh Satija, Meenu Mehta, Faruk L. Hakkim, Prashant Kesharwani, Kamal Dua, Dinesh K. Chellappan, Nitin B. Charbe, Garima Shrivastava, S. Rajeshkumar, Alaa A. Aljabali, Bahaa Al-trad, Kavita Pabreja, Murtaza M. Tambuwala

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD-2 and PHD-3. In the present report, we investigated the associated changes in levels of PHDs during the development and recovery of chemically induced colitis in mice. The results indicated that in the experimental model of murine colitis, levels of both, PHD-1 and PHD-2 were found to be increased with the progression of the disease; however, the level of PHD-3 remained the same in group of healthy controls and mice with colitis. Thus, the findings advocated that inhibitors, which inhibited all three isoforms of PHD could not be ideal therapeutics for IBD since PHD-3 is required for normal gut function. Hence, this necessitates the development of new compounds capable of selectively inhibiting PHD-1 and PHD-2 for effective treatment of IBD.

LanguageEnglish
Pages2032-2036
Number of pages5
JournalInflammation
Volume42
Issue number6
Early online date3 Aug 2019
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Prolyl Hydroxylases
Colitis
Disease Progression
Inflammatory Bowel Diseases
Prolyl-Hydroxylase Inhibitors
Protein Isoforms
Theoretical Models
Control Groups

Keywords

  • colitis
  • Prolyl hydroxylase
  • In vivo
  • prolyl hydroxylases
  • disease activity index
  • inflammatory bowel disease

Cite this

Bakshi, Hamid A. ; Mishra, Vijay ; Satija, Saurabh ; Mehta, Meenu ; Hakkim, Faruk L. ; Kesharwani, Prashant ; Dua, Kamal ; Chellappan, Dinesh K. ; Charbe, Nitin B. ; Shrivastava, Garima ; Rajeshkumar, S. ; Aljabali, Alaa A. ; Al-trad, Bahaa ; Pabreja, Kavita ; Tambuwala, Murtaza M. / Dynamics of Prolyl hydroxylases levels during disease progression in experimental colitis. In: Inflammation. 2019 ; Vol. 42, No. 6. pp. 2032-2036.
@article{9053e843469f406699ddd22f020e4f57,
title = "Dynamics of Prolyl hydroxylases levels during disease progression in experimental colitis",
abstract = "Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD-2 and PHD-3. In the present report, we investigated the associated changes in levels of PHDs during the development and recovery of chemically induced colitis in mice. The results indicated that in the experimental model of murine colitis, levels of both, PHD-1 and PHD-2 were found to be increased with the progression of the disease; however, the level of PHD-3 remained the same in group of healthy controls and mice with colitis. Thus, the findings advocated that inhibitors, which inhibited all three isoforms of PHD could not be ideal therapeutics for IBD since PHD-3 is required for normal gut function. Hence, this necessitates the development of new compounds capable of selectively inhibiting PHD-1 and PHD-2 for effective treatment of IBD.",
keywords = "colitis, Prolyl hydroxylase, In vivo, prolyl hydroxylases, disease activity index, inflammatory bowel disease",
author = "Bakshi, {Hamid A.} and Vijay Mishra and Saurabh Satija and Meenu Mehta and Hakkim, {Faruk L.} and Prashant Kesharwani and Kamal Dua and Chellappan, {Dinesh K.} and Charbe, {Nitin B.} and Garima Shrivastava and S. Rajeshkumar and Aljabali, {Alaa A.} and Bahaa Al-trad and Kavita Pabreja and Tambuwala, {Murtaza M.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1007/s10753-019-01065-3",
language = "English",
volume = "42",
pages = "2032--2036",
journal = "Inflammation",
issn = "1573-2576",
number = "6",

}

Bakshi, HA, Mishra, V, Satija, S, Mehta, M, Hakkim, FL, Kesharwani, P, Dua, K, Chellappan, DK, Charbe, NB, Shrivastava, G, Rajeshkumar, S, Aljabali, AA, Al-trad, B, Pabreja, K & Tambuwala, MM 2019, 'Dynamics of Prolyl hydroxylases levels during disease progression in experimental colitis', Inflammation, vol. 42, no. 6, pp. 2032-2036. https://doi.org/10.1007/s10753-019-01065-3

Dynamics of Prolyl hydroxylases levels during disease progression in experimental colitis. / Bakshi, Hamid A.; Mishra, Vijay; Satija, Saurabh; Mehta, Meenu; Hakkim, Faruk L.; Kesharwani, Prashant; Dua, Kamal; Chellappan, Dinesh K.; Charbe, Nitin B.; Shrivastava, Garima; Rajeshkumar, S.; Aljabali, Alaa A.; Al-trad, Bahaa; Pabreja, Kavita; Tambuwala, Murtaza M.

In: Inflammation, Vol. 42, No. 6, 01.12.2019, p. 2032-2036.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dynamics of Prolyl hydroxylases levels during disease progression in experimental colitis

AU - Bakshi, Hamid A.

AU - Mishra, Vijay

AU - Satija, Saurabh

AU - Mehta, Meenu

AU - Hakkim, Faruk L.

AU - Kesharwani, Prashant

AU - Dua, Kamal

AU - Chellappan, Dinesh K.

AU - Charbe, Nitin B.

AU - Shrivastava, Garima

AU - Rajeshkumar, S.

AU - Aljabali, Alaa A.

AU - Al-trad, Bahaa

AU - Pabreja, Kavita

AU - Tambuwala, Murtaza M.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD-2 and PHD-3. In the present report, we investigated the associated changes in levels of PHDs during the development and recovery of chemically induced colitis in mice. The results indicated that in the experimental model of murine colitis, levels of both, PHD-1 and PHD-2 were found to be increased with the progression of the disease; however, the level of PHD-3 remained the same in group of healthy controls and mice with colitis. Thus, the findings advocated that inhibitors, which inhibited all three isoforms of PHD could not be ideal therapeutics for IBD since PHD-3 is required for normal gut function. Hence, this necessitates the development of new compounds capable of selectively inhibiting PHD-1 and PHD-2 for effective treatment of IBD.

AB - Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD-2 and PHD-3. In the present report, we investigated the associated changes in levels of PHDs during the development and recovery of chemically induced colitis in mice. The results indicated that in the experimental model of murine colitis, levels of both, PHD-1 and PHD-2 were found to be increased with the progression of the disease; however, the level of PHD-3 remained the same in group of healthy controls and mice with colitis. Thus, the findings advocated that inhibitors, which inhibited all three isoforms of PHD could not be ideal therapeutics for IBD since PHD-3 is required for normal gut function. Hence, this necessitates the development of new compounds capable of selectively inhibiting PHD-1 and PHD-2 for effective treatment of IBD.

KW - colitis

KW - Prolyl hydroxylase

KW - In vivo

KW - prolyl hydroxylases

KW - disease activity index

KW - inflammatory bowel disease

UR - https://link.springer.com/article/10.1007/s10753-019-01065-3

UR - https://www.ncbi.nlm.nih.gov/pubmed/31377947

UR - http://www.scopus.com/inward/record.url?scp=85073683482&partnerID=8YFLogxK

U2 - 10.1007/s10753-019-01065-3

DO - 10.1007/s10753-019-01065-3

M3 - Article

VL - 42

SP - 2032

EP - 2036

JO - Inflammation

T2 - Inflammation

JF - Inflammation

SN - 1573-2576

IS - 6

ER -